Transplant Eligible vs Ineligible: Clinical Implications

Panelists discuss how ADVANCE data influence treatment selection for both transplant-eligible and -ineligible patients with newly diagnosed multiple myeloma (NDMM). They note that quadruplet regimens provide durable responses even in patients who defer or are ineligible for transplant. They emphasize flexibility in sequencing and maintenance, suggesting that daratumumab plus carfilzomib, lenalidomide, and dexamethasone could become foundational across patient subsets. The conversation explores how transplant decisions are increasingly individualized, guided by minimal residual disease status, tolerance, and patient preference.